Metformin + BI2536 may have significant activity in mCRPC

According to an new article in the Journal of Biological Chemistry, the combination of metformin with a polo-like kinase 1 (Plk1) inhibitor known currently as BI2536 appears to be able to suppress the spread of prostate cancer that resists all other available treatments.

Obviously, this is very preliminary data, based on laboratory experiments in cell cultures and mice. The only currently available information comes from a media release issued by Purdue University — and we are always a little cautious about the claims made in media releases.

The effects reported in animal experiments will need to be replicated in men with metastatic, castration-resistant prostate cancer (mCRPC) before anyone should start to get too excited.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: